Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma - Wikidata - awgldk - TriplyDB

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma

http://www.wikidata.org/entity/Q33408675

about

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Beta-glucan contamination of pharmaceutical products: How much should we accept?Trial watch: Immunostimulatory cytokines in cancer therapy.Trial Watch: Peptide-based anticancer vaccines.GD2-targeted immunotherapy and radioimmunotherapy Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.Immunotherapy in pediatric malignancies: current status and future perspectives In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.New immunotherapeutic strategies for the treatment of neuroblastoma.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Anti-GD2 immunotherapy for neuroblastoma.

P2860

Q26993238-FACEB9F4-9278-4365-9B35-908873C6B061 Q28077957-198E2BC9-5978-4815-9C3A-35EEFBA9C26A Q33880165-7218C755-B891-4899-8624-ABC068508325 Q34483345-11307A12-D3DB-4FB7-A9C4-33F674425600 Q34625339-D45A2AC8-A567-4023-A0EC-A9F16AE47D07 Q35755392-4D6A78E7-1538-4F13-A5B1-496E409D7C97 Q36691818-3CBC420D-5DC6-4667-8FD8-9AEB4FBEEDF1 Q37059790-9369D337-CD0F-4181-A89C-6CB7E092772E Q38389316-5746646A-A6AF-4D5D-9133-356462DF0CD2 Q38961012-C63B2DA9-6A88-4CB7-9175-5D847DAAC946 Q42558833-3506BA64-5EEE-4A6A-BF95-08C93EC4CA1F Q47554435-8C703931-98CB-4EC6-866A-477DF6924E32

P2860

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma

http://www.wikidata.org/entity/Q33408675

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Anti-GD2 antibody 3F8 and barl ...... h chemoresistant neuroblastoma

@ast

Anti-GD2 antibody 3F8 and barl ...... h chemoresistant neuroblastoma

@en

type

label

Anti-GD2 antibody 3F8 and barl ...... h chemoresistant neuroblastoma

@ast

Anti-GD2 antibody 3F8 and barl ...... h chemoresistant neuroblastoma

@en

prefLabel

Anti-GD2 antibody 3F8 and barl ...... h chemoresistant neuroblastoma

@ast

Anti-GD2 antibody 3F8 and barl ...... h chemoresistant neuroblastoma

@en

P1433

Q33408675-E3542052-4F4B-4643-BB64-3704E911BD2E

P1476

Q33408675-F19F31C0-D87C-4244-98BB-267C0F76722C

P2093

Q33408675-37C15CFB-F3FC-4F06-BDB0-43846CB3E35C

Q33408675-3DE01C60-0D12-4F5A-BFA7-D188D61449BE

Q33408675-643B75C2-D0A0-497F-8B13-08D4C6EA6E6F

Q33408675-DA022762-4B48-4C1B-B95E-2450F646D924

P2860

Q33408675-01E67B16-3F09-4A55-9236-B6ACD57E84AF

Q33408675-05C8B791-BF24-47EC-BB67-0944D9661E2B

Q33408675-0B98042A-542D-474D-A79C-3715FE950EEB

Q33408675-15EF52AD-E781-4EFD-8557-CA5354BA8CB2

Q33408675-1DD36B21-E375-424B-A44D-558569F17319

Q33408675-1F706E67-F275-42F9-A5E6-DB21AC594352

Q33408675-25B4F2E2-82E2-451E-BE7E-2ED129B9175E

Q33408675-25C2C05D-AAD0-4177-84FC-23985F2FADFD

Q33408675-36FF28D2-CFE4-4DBA-8DB4-7DDAE2D8EF7F

Q33408675-397E1EFB-47AC-43B7-BCC7-AEAF15D3B9FF

P304

Q33408675-EFF08C19-9CF6-41EC-87A8-C7F201C8DF73

P31

Q33408675-C260A042-FC04-4DD7-BC9D-21459419BE83

P356

Q33408675-9B177D08-975A-4553-8B0D-F89BC8408118

P433

Q33408675-902DCDAA-DC77-46AD-85DE-6816A553EE34

P478

Q33408675-F23C6AF5-089B-4697-ABCF-68CDCBCCCC77

P50

Q33408675-3AFBE354-222E-4990-991E-DB98CCAFCFA3

Q33408675-B3794BBB-CB16-4229-B8BC-9CE0D9B4511A

P577

Q33408675-DDDB2DC2-42D9-41C9-BACB-855FCC03111C

P5875

Q33408675-8C5EBA68-85E2-4AC9-9F58-BC39B8CCAE69

P698

Q33408675-FCE6C4FF-7137-4CEA-A65D-79167B7276B0

P921

Q33408675-6940D988-9B35-4864-A982-FD2A0ABCED61

P932

Q33408675-2543BB2D-BBDC-4D81-B64F-8CCEA9D1BADE

P356

P1433

P1476

Anti-GD2 antibody 3F8 and barl ...... h chemoresistant neuroblastoma

@en

P2093

Brian H Kushner

http://www.w3.org/2001/XMLSchema#string

Irene Y Cheung

http://www.w3.org/2001/XMLSchema#string

Kim Kramer

http://www.w3.org/2001/XMLSchema#string

Nai-Kong V Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models

Dectin-1 mediates the biological effects of beta-glucans

The influence of glucan polymer structure and solution conformation on binding to (1-->3)-beta-D-glucan receptors in a human monocyte-like cell line.

Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein.

Maitake extracts and their therapeutic potential.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

P304

e23402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.23402

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J Vickers

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

242018013

http://www.w3.org/2001/XMLSchema#string

P698

23802080

http://www.w3.org/2001/XMLSchema#string

P921

P932

3661165

http://www.w3.org/2001/XMLSchema#string